Volume : 13, Issue : 10, October – 2026
Title:
CURRENT REGULATIONS FOR CLINICAL TRIALS
Authors :
Devakar Rohit Chandrakant*, V. Lavanya
Abstract :
Clinical trials (CTs) are conducted to explore new methods of intervention that are better than the existing ones and can also be easily tolerated by patients. CTs are conducted in accordance with the regulatory guidelines recommended for the same by the drug regulatory authority of the country where they have to be conducted. In USA, CTs are regulated by USFDA as per their 21 code of federal regulations part 312 (CFR) of Federal Food, Drug, and Cosmetic act. In EU, they are regulated by European Commission and EMA as per their CT directive 2001/20/EC of the European Parliament and of the council of 4 April 2001 and GCP directive 2005/28/EC of 8 April 2005. In India, they are regulated by CDSCO (Schedule Y of the Drug and Cosmetics Rules, 1945) and ICMR (Ethical Guidelines for Biomedical Research on Human Subjects), respectively. In Singapore, CTs are regulated by HSA as per the Medicines Act and Medicines (Clinical Trials) Regulations Chapter 176, sections 18 and 74. The role of these authorities is to ensure the quality, safety, and effectiveness of all medicines in their respective countries. In this work, clinical trial regulations in USA, EU, India, and Singapore were compared on the basis of parameters such as regulatory bodies involved, regulations for CTs, clinical trial application format, application fee, approval time, the various forms required, role and responsibilities of IRB/IEC, record retention time, and GCP guidelines. The success rate of CTs in USA and Europe is higher in comparison to India, and Singapore which may be due to well-trained investigators, fast regulatory approval process and volunteer participation by the subjects. Some case studies related to the clinical trials conducted in these countries have also been incorporated.
Cite This Article:
Please cite this article in press Devakar Rohit Chandrakant et al., Current Regulations For Clinical Trials.,. Indo Am. J. P. Sci, 2026; 13(10).
REFERENCES:
1. “Clinical Trials” (PDF). Bill and Melinda Gates Foundation. Retrieved 1 January 2014.
2. Dimasi, Joseph A; Grabowski, Henry G; Hansen, Ronald W (2016). “Innovation in the pharmaceutical industry: New estimates of R&D costs”. Journal of Health Economics. 47: 20–33. doi:10.1016/j.jhealeco.2016.01.012. hdl:10161/12742. PMID 26928437.
3. Emanuel EJ (9 September 2015). “The Solution to Drug Prices”. The New York Times. Of the drugs started in clinical trials on humans, only 10 percent secure F.D.A. approval. …
4. FDA Page last updated 25 April 2014 FDA’s Drug Review Process: Continued
5. PhRMA. February 2007 Drug Discovery and Development
6. Merck Manual. Last full review/revision October 2013 by Daniel A. Hussar, PhD Overview of Over-the-Counter Drugs
7. Avorn J. (2004). Powerful Medicines, pp. 129–33. Alfred A. Knopf.
8. Van Spall HG, Toren A, Kiss A, Fowler RA (March 2007). “Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review”. JAMA. 297 (11): 1233–40. doi:10.1001/jama.297.11.1233. PMID 17374817.
9. The regulatory authority in the USA is the Food and Drug Administration; in Canada, Health Canada; in the European Union, the European Medicines Agency; and in Japan, the Ministry of Health, Labour and Welfare
10. “Medical Devices, Premarket Clinical Studies for Investigational Device Exemption”. US Food and Drug Administration. 17 March 2017. Retrieved 2 October 2017.